Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822609 · ClinicalTrials.gov registry record · Phase 2
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
A Phase 2 study of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT05822609: Recruiting Phase 2 study of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Washington.
NCT05822609 is a Phase 2 study of Type 1 Diabetes and Diabetic Kidney Disease that is actively recruiting participants, run by University of Washington. The registered enrollment target is 60 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05822609, a Phase 2 study of Type 1 Diabetes and Diabetic Kidney Disease, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Primary Outcome
Measured as mean of multiple urine albumin-creatinine ratio measurements in spot urine
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Semaglutide
Study Locations (4)
Washington
- University of Washington - Seattle
- Providence Sacred Heart Medical Center - Spokane
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Ontario
- Toronto General Hospital, University Health Network - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-04-05 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT05822609 shows while recruiting
NCT05822609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05822609 reports a single indexed study location in Washington, Colorado, Ontario.
Frequently Asked Questions
What is clinical trial NCT05822609 about?
NCT05822609 is a clinical study titled "Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes". The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
What is the current status of trial NCT05822609?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-04-05. Estimated completion is 2026-06.
What conditions does trial NCT05822609 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Diabetic Kidney Disease.
What interventions are being tested in trial NCT05822609?
The interventions under investigation include: Placebo (OTHER), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05822609?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05822609 being conducted?
This trial has 4 study locations across Colorado, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05822609's enrollment target sits among peer trials
60 73rd of 198 higher than 117 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
RECRUITING · Phase 2
-
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
RECRUITING · Phase 2
-
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
RECRUITING · Phase 2
-
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
RECRUITING · Phase 2
-
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
RECRUITING · Phase 2
-
Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI